Latest Conference Articles

These phase 3 findings from the INTEGUMENT-PED clinical trial highlight the efficacy and safety of roflumilast cream 0.05% for pediatric patients with atopic dermatitis.

Phase 3 WAYPOINT trial shows tezepelumab significantly reduces nasal polyp severity, congestion, and surgery needed in severe chronic rhinosinusitis with nasal polyp.

A meta-analysis found oral immunotherapy improves health-related quality of life post-food allergy treatment, but benefits during treatment remain unclear.

A study analyzed hypersensitivity reactions to biologics for atopic diseases, highlighting reaction types, severity, and biologic discontinuation rates.

In new data to be presented at AAAAI, the therapy was well-tolerated in people as young as 2 years old.

By week 52, remibrutinib and placebo-to-remibrutinib groups had similar levels of urticaria control.

Data from 3 pooled phase 3 studies in children, adolescents, and adults will be presented at the AAAI/WAO Joint Congress.

A study found many patients with chronic spontaneous urticaria need add-on or higher-dose therapies, revealing gaps in treatment. Findings will be presented at AAAAI 2025.

At week 12, a higher proportion of participants on rilzabrutinib 1200mg a day (60.9%) achieved AAS7 scores of 0 than placebo-treated participants (30.8%).

At 6 months, baseline monthly rates of 0.45 for mild, 1.54 for moderate, and 0.14 for severe attacks were reduced to 0.10, 0.08, and 0.00, respectively.

Bernstein discussed recent and upcoming research and management of angioedema in patients with urticaria.

Children with severe atopic dermatitis saw > 5 percentile height gains after 16 weeks of dupilumab, per a study to be presented at AAAAI 2025.

Around half of participants had insufficient vitamin D levels.

A study found the Skin Barrier Meter accurately measures skin barrier function in children with atopic dermatitis, offering a fast, non-invasive assessment within 5 seconds.

Fifteen of 16 patients with chronic ulcers in a small study had positive patch test to common wound care products.

A study found distinct DNA methylation patterns at birth linked to early-onset atopic dermatitis by age 2. Findings will be presented at AAAAI 2025.

New 2-year data from the BE HEARD program shed further light on the role bimekizumab in treatment algorithms for HS.

Avapritinib 25mg daily significantly improved quality of life (QoL), disease control, and basal serum tryptase (BST) levels.

A pooled analysis of LIBERTY-CSU CUPID Study A and Study C showed dupilumab reduces itch in patients with chronic spontaneous urticaria by week 24.

Approved under the name Dupixent in September 2024, the biologic is the first of its kind approved for COPD.

Piatek discussed findings from a healthcare resource utilization study and a sentiment analysis study presented at ASH 2024.

Pipe discussed a symposium at ASH 2024 about practical implementation of gene therapy in the field.

Schultz discussed the SCtalk trial and its findings at ASH 2024.

Zaheer discussed how this research may be used as a model to help study other therapy transitions as well.

Bendapudi gave an overview of 2 studies presented at ASH 2024 from his Harvard lab.

Rani discussed an in-depth study examining quality of sleep and quality of life in children and adolescents with SCD.

Iron deficiency is currently screened at a ferritin threshold of 15 ug/mL, well below an accepted 25 ug/mL threshold.

Yehuda Handelsman, MD reflects on the WCIRDC 2024’s comprehensive approach to advancing cardiometabolic care through multidisciplinary collaboration.